Global Monoclonal Antibody-Based Prostate Cancer Immunotherapy Market Research Report – Segmentation By product type (Anti- prostate-specific membrane antigen PSMA Monoclonal Antibody-Based, Anti-cytotoxic T-lymphocyte-associated antigen 4 CTLA-4 Monoclonal Antibody-Based, Anti-programmed cell death protein 1 (PD-1)/ligand PD-L1 PD-1/PD-L1 Monoclonal Antibody-Based); By Application (localized prostate cancer, metastatic prostate cancer, castration-resistant prostate cancer); By Distribution Channels (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By End-User (Hospitals and Clinics, Cancer Research Centers, Academic and Research institutes); and Region - Size, Share, Growth Analysis | Forecast (2024 – 2030)
Published: 2024 - Jan
Report Code: IM-14670
Format:
Region: Global
Ask an Expert
Choose License Type
$
2850
$
5250
$
4500
$
1800
